HMN 2026: How to reverse loss of blood flow to brain, an early sign of Alzheimer’s disease

Mouse model successful in reversing loss of blood flow to brain, an early sign of Alzheimer's disease
Piezo1 activation reduces capillary stalling and enhances cerebral blood flow in 5xFAD mice. Credit: Alzheimer’s & Dementia (2025). DOI: 10.1002/alz.71016

Supriya Chakraborty might have been studying insects in a lab had it not been for an immunology college instructor in India who taught him about the superheroes inside him—immune cells that wage a battle against bacteria, parasites, and a host of other adversaries that invade our bodies. “That really fascinated me,” Chakraborty recalled. “My focus shifted from entomology to wanting to solve illnesses that affect humans, specifically neurodegenerative disorders.”

Different journeys into brain research

Zeynab Tabrizi would take quite a different path to studying conditions that damage and destroy parts of the human nervous system. She had long been a student of immunology and neuroscience in her native Iran, conducting research that explored the causes of disorders like schizophrenia and autism. “I had some experience working in industry,” she said, “but my heart was in academia.”

Now, their paths have intersected at the University of Miami. As Ph.D. students in the College of Arts and Sciences’ Department of Biology, Chakraborty and Tabrizi conduct research that could help blaze a trail to more effective treatments for Alzheimer’s disease, perhaps even leading to a cure for the memory-robbing disorder that affects more than 7 million older adults in the U.S.

Promising findings on blood flow

In a new collaborative study that used a mouse model with Alzheimer’s, the two researchers discovered that activating Piezo1—a mechanosensitive ion channel that is functionally expressed in blood vessels—improved microvascular flow and neurovascular coupling in a mouse model with Alzheimer’s.

Reduced blood flow and impaired vascular responses in the brain are early features of Alzheimer’s and contribute to the disease’s progression,” Tabrizi said. “While our study was able to improve and actually restore such functions in a mouse model with the disease, we believe such a method may hold great promise as a therapeutic strategy for humans.”

In their study, now published in Alzheimer’s & Dementia, the researchers also employed the pharmacological activation of Piezo1 to improve functional hyperemia—the localized increase in blood flow to a specific tissue or organ, such as the brain or muscles, in response to increased metabolic activity or functional demand.

“It’s another major steppingstone in the race to solve the mystery of Alzheimer’s,” Chakraborty said of their research. “But further investigation is needed, which is our goal.”

Building on earlier dementia research

For Tabrizi, the study comes on the heels of other dementia-related research she has conducted at the University. Working with former Department of Biology neuroscientist Oliver Bracko, she has investigated how the immune system may be a factor in the progression of neurodegenerative diseases like Alzheimer’s.

In that research, Tabrizi focused on white blood cells called neutrophils, which in previous studies she conducted have been shown to block blood vessels and contribute to the reduction of blood flow to the brain in mouse models of Alzheimer’s disease.

“Alzheimer’s is a disease that not only affects the patient but also family members, who are often the ones who end up caregiving for a loved one with the disorder,” she said. “So our work will aid people on all fronts of battling the disease.”

Publication details

Zeynab Tabrizi et al, Systemic Piezo1 activation improves cerebrovascular function in Alzheimer’s disease, Alzheimer’s & Dementia (2025). DOI: 10.1002/alz.71016

Journal information:
Alzheimer’s & Dementia


Key medical concepts

Alzheimer’s DiseasePIEZO1 Gene

Clinical categories

Neurology


The content is provided for information purposes only.